Advaxis (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a research report report published on Tuesday. The brokerage issued a sell rating on the stock.

NASDAQ ADXS opened at $0.06 on Tuesday. Advaxis has a 52 week low of $0.06 and a 52 week high of $0.76. The company has a market cap of $9.32 million, a price-to-earnings ratio of -0.64 and a beta of 2.14.

About Advaxis (Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

See Also